These results suggest colorectal cancer with MSI-H, MLH1 hypermethylation or BRAF mutations must be heavily and/or specifically infected with Fn, so that reduction in amplifiable Fn DNA by FFPE treatment may not change these associations. This evidence concerns the gene FN1 and colorectal cancer.